Kim et al. reported paradoxically higher MET uptake in grade 2 and 3 gliomas with IDH1 mutations and 1p/19q codeletions compared to IDH1-wildtype astrocytomas [19]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).